Inventisbio, Co., Ltd. Class ASSE: 688382

Announcement on Voluntary Disclosure of the Completion of Full Subject Enrollment in the Phase III Clinical Trial of D-2570 for Psoriasis

· Issued by Inventisbio, Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of the Completion of Full Subject Enrollment in the Phase III Clinical Trial of D-2570 for Psoriasis

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis